新型恶唑烷酮类抗耐药结核药物的研究进展  

New oxazolidinone drugs and perspectives for anti-tuberculosis agents

作　　者：郭少晨 陆宇 Guo Shaochen;Lu Yu(Beijing Key Laboratory of Drug Resistance Tuberculosis Research,Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing 101149)

机构地区：[1]首都医科大学附属北京胸科医院药物学研究室北京市结核病胸部肿瘤研究所耐药结核病北京市重点实验室,北京101149

出　　处：《中国抗生素杂志》2024年第5期490-497,共8页Chinese Journal of Antibiotics

摘　　要：全球耐药结核病形势严峻,临床中用于治疗耐药结核病的药物选择非常有限,导致了治疗的困难和挑战,开发新型抗结核药物对于耐药结核病的治疗具有关键性的作用。恶唑烷酮类药物及其结构改造物显示出对结核分枝杆菌耐药菌株具有良好的抗菌活性。本文对近期关于恶唑烷酮类药物作用机制、临床前体内外抗结核活性、药动学特点、安全性和临床试验研究进展进行综述。The global situation of drug-resistant tuberculosis is severe,with limited drug options available for the treatment of drug-resistant tuberculosis,resulting in challenges and difficulties in treatment.The development of new anti-tuberculosis drugs plays a crucial role in the treatment of drug-resistant tuberculosis.Oxazolidinone drugs and their structural derivatives have shown good antibacterial activity against drug-resistant strains of Mycobacterium tuberculosis.This article reviewed recent advances in the understanding of the mechanism of action,preclinical studies on the anti-tuberculosis activity,pharmacokinetic properties,safety,and clinical trials of oxazolidinone drugs.

关 键 词：耐药结核病 恶唑烷酮类药物 药动学 药效学 

分 类 号：R978.3[医药卫生—药品]